(1)
Golden, Colorado (ots/PRNewswire) - ArcScan, Inc., der Entwickler des hochmodernen ophthalmologischen Ultraschallbildgebungsgeräts ArcScan Insight® 100 mit Hauptsitz in Golden, Colorado, gibt die Ausführung einer Aktienkaufvereinbarung mit Shanghai Haohai Biological Technology Ltd. ( Haohai ) über eine Preferred Series B -Investition in ArcScan in Höhe von 11,15 Millionen USD bekannt. Inc. Haohai ist ein führendes chinesisches Unternehmen für Augenheilkunde und medizinische Ästhetik mit Sitz in Shanghai, das an den Börsen in Hongkong (6826.HK) und Shanghai (688366.SH) gehandelt wird.
YAFO Capital aus Shanghai und Auctus Capital Partners aus Chicago fungierten bei dieser Transaktion als Finanzberater für ArcScan, Inc.
ArcScan, Inc Signs Definitive Agreement for $11 15 Million Preferred Series B Investment with Shanghai Haohai Biological Technology Ltd prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
WOBURN, Mass., March 9, 2021 /PRNewswire/ Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced a deal with Shanghai Haohai Biological Technology Ltd. ( Haohai ) that will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eirion s products for the territory of China in exchange for an upfront payment in the amount of $8 million. The deal is structured in segments over the next approximately 18 months. Haohai is a leading Chinese aesthetic medicine company headquartered in Shanghai and is publicly traded on the Hong Kong (6826.HK) and Shanghai (688366.SS) stock exchanges.
Eirion Therapeutics, Inc Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.